NASDAQ:CBMGCellular Biomedicine Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cellular Biomedicine Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.71 -0.48 (-3.64 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$12.60Now: $12.71▼$13.4650-Day Range$13.13MA: $14.32▼$15.5652-Week Range$10.98Now: $12.71▼$18.99Volume78,889 shsAverage Volume82,436 shsMarket Capitalization$246.45 millionP/E RatioN/ADividend YieldN/ABeta1.58 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase I clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a strategic licensing and collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingCellular Biomedicine Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.67, Cellular Biomedicine Group has a potential upside of 70.5% from its current price of $12.71.Amount of Analyst CoverageCellular Biomedicine Group has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCellular Biomedicine Group has received 190 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCellular Biomedicine Group has received 223 “underperform” votes. (Add your “underperform” vote.)Community SentimentCellular Biomedicine Group has received 54.00% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote “Outperform” if you believe CBMG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCellular Biomedicine Group does not currently pay a dividend.Dividend GrowthCellular Biomedicine Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellular Biomedicine Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Cellular Biomedicine Group is held by insiders.Percentage Held by InstitutionsOnly 21.96% of the stock of Cellular Biomedicine Group is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cellular Biomedicine Group are expected to decrease in the coming year, from ($2.96) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellular Biomedicine Group is -4.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellular Biomedicine Group is -4.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellular Biomedicine Group has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.09 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBMG Previous Symbol CUSIPN/A CIK1378624 Webwww.cellbiomedgroup.com Phone347-905-5663Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$340,000.00 Price / Sales724.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book4.40Profitability EPS (Most Recent Fiscal Year)($2.63) Net Income$-49,980,000.00 Net MarginsN/A Return on Equity-83.10% Return on Assets-51.14%Miscellaneous Employees193 Outstanding Shares19,390,000Market Cap$246.45 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:CBMG Rates by TradingView Receive CBMG News and Ratings via Email Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter. Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions How has Cellular Biomedicine Group's stock been impacted by COVID-19 (Coronavirus)? Cellular Biomedicine Group's stock was trading at $14.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CBMG shares have decreased by 12.3% and is now trading at $12.71. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cellular Biomedicine Group? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cellular Biomedicine Group. When is Cellular Biomedicine Group's next earnings date? Cellular Biomedicine Group is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellular Biomedicine Group. How were Cellular Biomedicine Group's earnings last quarter? Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.18. View Cellular Biomedicine Group's earnings history. What price target have analysts set for CBMG? 3 brokerages have issued 12 month price targets for Cellular Biomedicine Group's shares. Their forecasts range from $19.00 to $27.00. On average, they anticipate Cellular Biomedicine Group's stock price to reach $21.67 in the next twelve months. This suggests a possible upside of 70.5% from the stock's current price. View analysts' price targets for Cellular Biomedicine Group. Has Cellular Biomedicine Group been receiving favorable news coverage? News headlines about CBMG stock have trended neutral on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutCellular Biomedicine Group. Are investors shorting Cellular Biomedicine Group? Cellular Biomedicine Group saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 408,700 shares, a drop of 15.3% from the April 30th total of 482,600 shares. Based on an average daily trading volume, of 69,300 shares, the short-interest ratio is currently 5.9 days. Approximately 4.0% of the company's stock are sold short. View Cellular Biomedicine Group's Current Options Chain. Who are some of Cellular Biomedicine Group's key competitors? Some companies that are related to Cellular Biomedicine Group include Compugen (CGEN), Translate Bio (TBIO), BAVARIAN NORDIC/S (BVNRY), Orchard Therapeutics (ORTX), Replimune Group (REPL), Krystal Biotech (KRYS), Sorrento Therapeutics (SRNE), Avrobio (AVRO), BioCryst Pharmaceuticals (BCRX), AVITA MED LTD/S (RCEL), Cellectis (CLLS), Aerie Pharmaceuticals (AERI), Vericel (VCEL), Osiris Therapeutics (OSIR) and Oyster Point Pharma (OYST). View all competitors. What other stocks do shareholders of Cellular Biomedicine Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Anavex Life Sciences (AVXL), Aduro BioTech (ADRO), Amarin (AMRN), Adaptimmune Therapeutics (ADAP), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN), Viewray (VRAY) and Agile Therapeutics (AGRX). Who are Cellular Biomedicine Group's key executives? Cellular Biomedicine Group's management team includes the following people: Mr. Bizuo Liu, CEO, CFO & Director (Age 54)Dr. Yihong Yao, Chief Scientific Officer (Age 51)Mr. Andrew K. Chan, Chief Legal Officer, Gen. Counsel, Sr. VP of Corp. Bus. Devel. & Sec. (Age 61)Dr. Li Zhang, Chief Production OfficerDerrick C. Li, Head of Strategy & Investor Relations What is Cellular Biomedicine Group's stock symbol? Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG." Who are Cellular Biomedicine Group's major shareholders? Cellular Biomedicine Group's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.16%), Nikko Asset Management Americas Inc. (2.46%), Sumitomo Mitsui Trust Holdings Inc. (2.46%), Nikko Asset Management Americas Inc. (2.46%), State Street Corp (1.12%) and Geode Capital Management LLC (0.85%). View institutional ownership trends for Cellular Biomedicine Group. Which institutional investors are selling Cellular Biomedicine Group stock? CBMG stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Morgan Stanley, State Street Corp, UBS Group AG, BlackRock Inc., and Vident Investment Advisory LLC. View insider buying and selling activity for Cellular Biomedicine Group. Which institutional investors are buying Cellular Biomedicine Group stock? CBMG stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Geode Capital Management LLC, Citigroup Inc., BNP Paribas Arbitrage SA, Russell Investments Group Ltd., and Rhumbline Advisers. View insider buying and selling activity for Cellular Biomedicine Group. How do I buy shares of Cellular Biomedicine Group? Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cellular Biomedicine Group's stock price today? One share of CBMG stock can currently be purchased for approximately $12.71. How big of a company is Cellular Biomedicine Group? Cellular Biomedicine Group has a market capitalization of $246.45 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-49,980,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe. What is Cellular Biomedicine Group's official website? The official website for Cellular Biomedicine Group is www.cellbiomedgroup.com. How can I contact Cellular Biomedicine Group? Cellular Biomedicine Group's mailing address is 1345 AVENUE OF AMERICAS 15TH FLOOR, NEW YORK NY, 10105. The biotechnology company can be reached via phone at 347-905-5663 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
